Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9328518 | 0.95 | RARB (0.50) | MAPK1RXRARXRBMAPTKMT2A | |
| SCHEMBL9257016 | 0.92 | TP53 (0.57) | TP53TSHRMAPK1RXRARXRB | |
| SCHEMBL9329676 | 0.89 | TP53 (0.62) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL8162563 | 0.89 | TP53 (0.62) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL9329632 | 0.89 | TP53 (0.62) | TP53TSHRPLA2G4BRARB | |
| SCHEMBL1842790 | 0.86 | RXRA (0.47) | TP53TSHRMAPK1RXRARXRB | |
| SCHEMBL11168893 | 0.85 | MAPK1 (0.45) | TP53TSHRMAPK1RXRARXRB | |
| SCHEMBL9331239 | 0.85 | RARB (0.65) | TP53TSHRPLA2G4BMAPTKMT2A | |
| SCHEMBL9330512 | 0.85 | RARB (0.65) | TP53TSHRPLA2G4BMAPTKMT2A | |
| SCHEMBL9329247 | 0.85 | RARB (0.65) | TP53TSHRPLA2G4BMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1226856-A | — | — | None | — | — | JP | disclosed |
| JP-1019041-A | — | — | None | — | — | JP | disclosed |
| US-8618159-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| CN-101903339-B | Substituted N-phenyl-bipyrrolidine carboxamides and their therapeutic use | SANOFI AVENTIS | 2012-06-27 | — | — | CN | disclosed |
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| CN-101903339-A | Substituted N-phenyl-bipyrrolidine carboxamides and their therapeutic use | SANOFI AVENTIS | 2010-12-01 | — | — | CN | disclosed |
| EP-2212282-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| CN-100506792-C | Substituted N-aryl heterocycles, method for the production thereof and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2009-07-01 | — | — | CN | disclosed |
| CN-1774418-A | Substituted N-arylheterocycles, method for production and use thereof as medicaments | AVENTIS PHARMA GMBH (DE) | 2006-05-17 | — | — | CN | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| US-5332675-A | Liquid crystals | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-07-26 | — | — | US | disclosed |
| EP-0289307-B1 | OPTICALLY ACTIVE AROMATIC CARBOXYLIC ACID DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-07-08 | — | — | EP | disclosed |
| EP-0297745-B1 | OPTICALLY ACTIVE ETHER DERIVATIVES, PREPARATION PROCESSES THEREFOR, LIQUID CRYSTAL MATERIALS AND AN OPTICAL SWITCHING ELEMENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-5019298-A | Optically active aromatic carboxylic acid derivatives and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-05-28 | — | — | US | disclosed |
| US-5013479-A | Aromatic ether esters containing two or three benzene rings | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-05-07 | — | — | US | disclosed |
| JP-H01226856-A | OPTICALLY ACTIVE ETHERS AND PRODUCTION THEREOF | SUMITOMO CHEM CO LTD | 1989-09-11 | — | — | JP | disclosed |
| EP-0297745-A1 | Optically active ether derivatives, preparation processes therefor, liquid crystal materials and an optical switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0289307-A2 | Optically active aromatic carboxylic acid derivatives and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | TP53 4059/4885TSHR 224/4885MAPK1 2160/4885 |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | TP53 4123/4885TSHR 3707/4885MAPK1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.